Transfusion Clinique et Biologique最新文献

{"title":"Application of anti-D immunoglobulin in D-negative pregnant women in China","authors":"Lihui Fu,&nbsp;Chunya Ma,&nbsp;Yang Yu","doi":"10.1016/j.tracli.2023.11.002","DOIUrl":"10.1016/j.tracli.2023.11.002","url":null,"abstract":"<div><p>This article summarizes the current situation of anti-D immunoglobulin (anti-D-Ig) use in RhD-negative pregnant women at home and abroad. The article describes the concept, research and development history, and domestic and foreign applications of anti-D-Ig and points out that anti-D-Ig has not been widely used in China, mainly due to reasons such as unavailability in the domestic market and non-standard current application strategies. The article focuses on analyzing the genetic and immunological characteristics of RhD-negative populations in China. The main manifestations were that the total number of hemolytic disease of the newborn (HDN) relatively high and D variant type. In particular, there are more Asian-type DEL, the importance of clinical application of anti-D-Ig was pointed out, and its antibody-mediated immunosuppressive mechanism was analyzed, which mainly includes red blood cell clearance, epitope blocking/steric hindrance, and Fc γ R Ⅱ B receptor mediated B cell inhibition, anti-D-Ig glycosylation, etc.; clarify the testing strategies of RhD blood group that should be adopted in response to the negative initial screening of pregnant and postpartum women; this article elaborates on the necessity of using anti-D-Ig in RhD-negative mothers after miscarriage or miscarriage, as well as the limitations of its application both domestically and internationally. It also proposes a solution strategy for detecting RhD blood group incompatibility HDFN as early as possible, diagnosing it in a timely manner, and using anti-D-Ig for its prevention and treatment. If the DEL gene is defined as an Asian-type DEL, anti-D-Ig prophylaxis in women would be unnecessary. Finally, based on the specificity of RhD-negative individuals, the article looks forward to the application trend of anti-D-Ig in China. It also called for related drugs to be listed in China as soon as possible and included in medical insurance.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allelic frequency variation of ACKR1 in three Algerian populations: Zenata, Reguibat, and Oran","authors":"Leila Adda Neggaz ,&nbsp;Tahria Deba ,&nbsp;Asmahan Bekada ,&nbsp;Djabaria Naima Meroufel Sebaa ,&nbsp;Sounnia Mediene Benchekor ,&nbsp;Soraya Benhamamouch","doi":"10.1016/j.tracli.2023.10.003","DOIUrl":"10.1016/j.tracli.2023.10.003","url":null,"abstract":"<div><h3>Introduction</h3><p>The discovery of the Duffy antigen is of great significance, given its essential role in immune response and various physiological processes. Genetic mutations in the Duffy gene not only affect antigen expression but also result in different antigen types. This underscores the importance of genetic characterization for clinical studies and exploring genetic diversity within the population. This study primarily aims to genetically characterize the Duffy blood group within three Algerian populations: the Zenata, Reguibat, and Oran populations.</p></div><div><h3>Methods</h3><p>The genetic polymorphism of the Duffy erythrocyte group was examined, focusing on five allelic versions of the ACKR1 locus: <em>FY*01</em>, <em>FY*02</em>, <em>FY*X</em>, and silent alleles <em>FY*01 N.01</em> and <em>FY*02 N.01</em>. A total of 223 Algerian individuals, including 90 from the Oran population, 66 from the Zenata population, and 67 from the Reguibat population, were analyzed using the polymerase chain reaction with sequence-specific primer (PCR-SSP) method.</p><p>The results revealed the presence of the silent alleles (<em>FY*01 N.01 and FY*02 N.01</em>) in all three populations, with a total frequency of 78.03% in the Zenata population. Additionally, the <em>FY*X</em> allele was exclusively detected in the Reguibat population, with a frequency of 0.75%</p></div><div><h3>Conclusion</h3><p>This study provides valuable insights into the allele and genotypic frequencies of the Duffy system in the Zenata, Reguibat and Oranpopulations, contributing to our understanding of the genetic history and origins of the Algerian population. Further research incorporating additional genetic markers and establishing a comprehensive database would enhance our knowledge in this area.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of Indian National plasma policy at blood bank of a tertiary care hospital: A step towards strengthening of blood transfusion services","authors":"Naveen Bansal ,&nbsp;Kajal Khajuria ,&nbsp;Rajbir Kaur Cheema ,&nbsp;Ashish Sharma ,&nbsp;Baltaran Singh Bajwa","doi":"10.1016/j.tracli.2023.10.002","DOIUrl":"10.1016/j.tracli.2023.10.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The World Health Organization has advocated that every country should make its own policy for ensuring safe and adequate supply of plasma derived medicinal products through mobilization and usage of locally collected plasma. The National Plasma Policy (NPP) of India was published in 2014 with a dual objective to achieve self sufficiency in the production of plasma derived medicinal products and at the same time to augment the component preparation facilities in India and overall upliftment of blood transfusion services in the country. Thus the present study was done to access the impact of implementation of NPP in our blood bank on the blood transfusion services in our hospital.</p></div><div><h3>Materials and methods</h3><p>The present study was a retrospective observational study conducted in the department of transfusion medicine of a tertiary care hospital in India involving analysis of data from 1st January 2019 till 31st December 2022. For the purpose of data analysis the time period was divided into 2 periods: (i) Pre-NPP implementation period from 1st January 2019 till 31st December 2020; (ii) Post-NPP period from 1st January 2021 till 31st December 2022. The following parameters were compared for the two periods: (i) component preparation rate; (ii) percentage of component therapy; (iii) total number of FFP transferred to plasma fractionation centers; (iv) total amount of exchange amount generated in lieu of transferred FFP to plasma fractionation centers.</p></div><div><h3>Results</h3><p>The component preparation rate after NPP implementation was significantly higher as compared to the pre NPP implementation period (93.81% vs 56.70%; p = 0.007). The percentage of component therapy in the patients was also significantly higher as compared to the pre-NPP implementation period (97.9% vs 73.6%; p = 0.005). The total amount of exchange amount generation in Indian rupee (INR) after NPP implementation was INR 1419462 (15835€) while it was INR 636898 (7105€) in the pre NPP implementation period. This amount was utilized for procurement of various blood bank equipment, in addition 2 lab technicians were also hired for the blood bank.</p></div><div><h3>Conclusions</h3><p>The implementation of NPP resulted in upliftment of blood transfusion services in our hospital. Other low and middle income countries can benefit from implementation of similar plasma policy in their countries.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmet needs in β-thalassemia and the evolving treatment landscape","authors":"Ryan Njeim ,&nbsp;Bilal Naouss ,&nbsp;Rayan Bou-Fakhredin ,&nbsp;Antoine Haddad ,&nbsp;Ali Taher","doi":"10.1016/j.tracli.2023.12.003","DOIUrl":"10.1016/j.tracli.2023.12.003","url":null,"abstract":"<div><p>β-thalassemias are genetic disorders causing an imbalance in hemoglobin production, leading to varying degrees of anemia, with two clinical phenotypes: transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT). Red blood cell transfusions and iron chelation therapy are the conventional treatment options for the management of β-thalassemia. Currently available conventional therapies in thalassemia have many challenges and limitations. Accordingly, multiple novel therapeutic approaches are currently being developed for the treatment of β-thalassemias. These strategies can be classified into three categories based on their efforts to address different aspects of the underlying pathophysiology of β-thalassemia: correction of the α/β globin chain imbalance, addressing ineffective erythropoiesis, and targeting iron dysregulation. Managing β- thalassemia presents challenges due to the many complications that can manifest, limited access and availability of blood products, and lack of compliance/adherence to treatment. Novel therapies targeting ineffective erythropoiesis and thus improving anemia and reducing the need for chronic blood transfusions seem promising. However, the complex nature of the disease itself requires personalized treatment plans for each patient. Collaborations and partnerships between thalassemia centers can also help share knowledge and resources, particularly in regions with higher prevalence and limited resources. This review will explore the different conventional treatment modalities available today for the management of β-thalassemia, discuss the unmet needs and challenges associated with them in addition to exploring the role of some novel therapeutic agents in the field.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138818313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating patient blood management practices using PBM metrics in a tertiary care center","authors":"Ashna George ,&nbsp;Shamee Shastry ,&nbsp;Ganesh Mohan ,&nbsp;Sushma Belurkar","doi":"10.1016/j.tracli.2023.12.002","DOIUrl":"10.1016/j.tracli.2023.12.002","url":null,"abstract":"<div><h3>Background</h3><p>PBM metrics play a crucial role in assessing and monitoring the effectiveness of PBM programs in healthcare settings. The present study aimed to assess the indicators to achieve effective enforcement of PBM at a tertiary care referral hospital.</p></div><div><h3>Subjects and Method</h3><p>A prospective observational study was conducted on patients admitted for elective surgery at a tertiary care referral centre. PBM metrics were developed and assessed for various parameters, including documentation, patient evaluation, blood ordering schedule, and appropriateness. Experts in transfusion medicine and haematology checked content validity. Eleven different parameters were analysed, and a score was assigned based on the performance. The outcome was categorized as poor, satisfactory, or good.</p></div><div><h3>Results</h3><p>The study included 612 patients meeting the inclusion criteria and recruited from Orthopaedics, General Surgery, OBG, Urology, and ENT departments. All departments completed pre-operative anaemia tests, with General Surgery and Orthopaedics conducting the most red cell transfusions. During the study, all of the blood units were used, and there was no waste. The C/T ratio was greater in the Departments of General Surgery, Urology, and Otorhinolaryngology. Pre-operative anaemia was found in 44.12% of patients, 44 patients had red cell transfusions, with 65% getting single-unit PRBC transfusions. All departments received a PBM score between 17–19, showing adequate PBM but with room for improvement.</p></div><div><h3>Conclusion</h3><p>The current study utilized Patient Blood Management (PBM) metrics to critically assess the existing practices and identify the key gaps and areas for improvement in a tertiary care centre.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1246782023005517/pdfft?md5=ad44b82e0464d3134feed06d90c5d773&pid=1-s2.0-S1246782023005517-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138715584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Leukocytapheresis to relieve priapism due to leukostasis in CML patients: Our experience in a tertiary care centre","authors":"Suhasini Sil ,&nbsp;Aswin K Mohan ,&nbsp;Gita Negi ,&nbsp;Pradip Banerjee ,&nbsp;Daljit Kaur ,&nbsp;Ankur Mittal ,&nbsp;Ashish Jain","doi":"10.1016/j.tracli.2023.11.001","DOIUrl":"10.1016/j.tracli.2023.11.001","url":null,"abstract":"<div><p>Hyperleukocytosis in leukemic patients may cause tumour lysis syndrome, disseminated intravascular coagulopathy, and leukostasis, resulting in decreased tissue perfusion and increasing the risk of mortality. Since the myeloid blasts are larger than lymphoid blasts and are less deformable, complications of leukostasis are seen more frequently in myeloid leukemia. Priapism is a less common complication associated with leukostasis in leukaemia patients that should be treated as soon as possible to avoid ischemic injuries. Although chemotherapeutic drugs such as hydroxyurea and imatinib are used to treat hyperleukocytosis in CML patients, leukocytapheresis (LCP) can achieve rapid cytoreduction. Prophylactic LCP could not offer any advantage over aggressive chemotherapy, but therapeutic leukocyte depletion has a proven role in patients having symptomatic leukostasis due to high tumour burden. Three patients with ischaemic priapism were reported at our institute's emergency department, where detumescence could not be achieved by distal shunting or aspiration with phenylephrine instillation. The procedure of therapeutic LCP was performed in all three patients on an emergency basis, which resolved painful priapism by rapid cytoreduction.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72016639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What are the new challenges facing blood transfusion?","authors":"Olivier Garraud ,&nbsp;Miquel Lozano ,&nbsp;Tomislav Vuk","doi":"10.1016/j.tracli.2024.01.008","DOIUrl":"10.1016/j.tracli.2024.01.008","url":null,"abstract":"","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139648351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presurgical circulating platelet-derived microparticles level as a risk factor of blood transfusion in patients with valve heart disease undergoing cardiac surgery","authors":"Mehrnaz Abdolalian ,&nbsp;Elham Khalaf-Adeli ,&nbsp;Fatemeh Yari ,&nbsp;Saeid Hosseini ,&nbsp;Pardis kiaeefar","doi":"10.1016/j.tracli.2023.11.004","DOIUrl":"10.1016/j.tracli.2023.11.004","url":null,"abstract":"<div><h3>Background</h3><p>Cell-derived microparticles (MPs) are membrane vesicles that have emerged as a potential biomarker for various diseases and their clinical complications. This study investigates the role of MPs as a risk factor for blood transfusion in patients with valve heart disease undergoing cardiac surgery.</p></div><div><h3>Methods</h3><p>Forty adult patients undergoing heart valve surgery with cardiopulmonary bypass (CPB) were enrolled, and venous blood samples were collected prior to surgical incision. Plasma rich in MPs was prepared by double centrifugation, and the concentration of MPs was determined using the Bradford method. Flow cytometry analysis was performed to determine MPs count and phenotype. Patients were divided into “with transfusion” (n = 18) and “without transfusion” (n = 22) groups based on red blood cell (RBC) transfusion.</p></div><div><h3>Results</h3><p>There was no significant difference in MPs concentration between the “with transfusion” and “without transfusion” groups. Although the count of preoperative platelet-derived MPs (PMPs), monocyte-derived MPs (MMPs), and red cell-derived MPs (RMPs) was higher in “without transfusion” group, these differences were not statistically significant. The preoperative PMPs count was negatively correlated with RBC transfusion (P = 0.005, r = -0.65). Multivariate logistic regression analysis revealed that the count of CD41⁺ PMPs, Hemoglobin (Hb), and RBC count were risk factors for RBC transfusion.</p></div><div><h3>Conclusion</h3><p>This study suggests that the presurgical levels of PMPs, Hb, and RBC count can serve as risk factors of RBC transfusion in patients with valve heart disease undergoing cardiac surgery. The findings provide insights into the potential use of MPs as biomarkers for blood transfusion prediction in cardiac surgery.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular analysis and transfusion management in a rare case of cis-AB blood group: A report from India","authors":"Suvro Sankha Datta ,&nbsp;Mercy Rophina ,&nbsp;Vinod Scaria","doi":"10.1016/j.tracli.2023.10.001","DOIUrl":"10.1016/j.tracli.2023.10.001","url":null,"abstract":"<div><p>Molecular characterization of a rare <em>cis</em>-AB blood group has not been done in the Indian subcontinent. Herein, we report a case of A₂B₃ blood group in an Indian patient which was subsequently confirmed to be a case of <em>cis</em>-AB phenotype. Blood grouping was performed by the column agglutination technique (CAT), conventional tube technique (CTT) and subsequently, whole exome sequencing for molecular analysis. The patient was initially typed as AB, RhD positive in forward grouping. However, serum grouping showed agglutination (2+) with the B red cells in CAT. In CTT, an extra reaction was observed with A₁ red cells and a strong agglutination was seen with Anti-H lectin. Thus, the blood group was identified serologically as A₂B₃. During the next-generation sequencing, a total of 10 exonic variants in the <em>ABO</em> gene were filtered, of which 2 (rs8176747 and rs7853989) were found to be non-synonymous and occurring on the same allele. The other allele was found to be <em>ABO*A1.01</em>. The sample analyzed in the study was found to carry two previously reported nucleotide changes of <em>cis</em>-AB (c.803G &gt; C and c.526C &gt; G) on the same allele which had not been reported before. Transfusion requirement was managed with type O red cells and type AB plasma.</p></div>","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first isoimmunized pregnancy","authors":"Jon F. Watchko","doi":"10.1016/j.tracli.2023.12.001","DOIUrl":"10.1016/j.tracli.2023.12.001","url":null,"abstract":"","PeriodicalId":23262,"journal":{"name":"Transfusion Clinique et Biologique","volume":null,"pages":null},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138579459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}